What is the current market size?

The Anti-VEGF Drugs for Angiogenesis-related Disease market size was valued at USD 3.8 billion in 2023, driven by rising adoption in ophthalmology and oncology.

What is the expected growth rate?

The market is projected to grow at a CAGR of 6.2% from 2024 to 2032, fueled by pipeline innovations and expanding therapeutic applications.

What are the key growth drivers?

Key drivers include the rising prevalence of age-related macular degeneration, demand for biosimilars, and advancements in biologics manufacturing.

What challenges does the market face?

High treatment costs, patent expirations, and competition from emerging therapies hinder market growth, though biosimilar approvals are easing some barriers.

Which regions lead the market?

North America dominates the market, followed by Europe, due to advanced healthcare infrastructure and high R&D investment in anti-VEGF therapeutics.

Who are the top companies involved?

Leading firms include Roche, Allergan (AbbVie), Novartis, and Bayer, which hold significant market share through products like Lucentis and Eylea.

What future opportunities exist?

Opportunities lie in gene therapy development, expanded indications for rare angiogenesis disorders, and emerging markets in Asia-Pacific.

How is technology impacting the market?

AI-driven drug discovery and precision medicine are accelerating R&D, enabling personalized anti-VEGF therapies with improved efficacy and fewer side effects.

What is the regulatory landscape?

Regulatory bodies like the FDA and EMA prioritize safety and efficacy, with expedited pathways for novel therapies addressing unmet clinical needs in oncology and ophthalmology.

Which Companies Lead the Anti-VEGF Drugs for Angiogenesis-related Disease Market in 2026?

Anti-VEGF Drugs for Angiogenesis-related Disease by Application (Tumor, Eye Diseases, Others), by Types (Ranibizumab, Brolucizumab, Aflibercept, Conbercept, Faricimab, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $12000 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $12000 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Anti-VEGF Drugs for Angiogenesis-related Disease Market Overview

The Anti-VEGF Drugs for Angiogenesis-related Disease market encompasses therapeutics targeting vascular endothelial growth factor (VEGF) to inhibit pathological angiogenesis, primarily in ophthalmic conditions like age-related macular degeneration (AMD) and diabetic retinopathy. This market holds strategic relevance due to its role in addressing high-unmet medical needs in chronic diseases. The Anti-VEGF Drugs for Angiogenesis-related Disease market size was estimated at $8.2 billion in 2025, driven by increasing prevalence of retinal disorders and advancements in biotherapeutics. The growth outlook for 2026–2033 projects a CAGR of 6.8%, with macro drivers including regulatory approvals for novel delivery systems and rising adoption of biosimilars. Key forces reshaping the industry include technology shifts toward gene therapy integration and supply-chain dynamics favoring cost-effective manufacturing.

Loading chart…

The market forecast underscores North America as the largest regional market in 2025, fueled by high healthcare expenditure and robust R&D pipelines. Conversely, Asia-Pacific is poised to emerge as the fastest-growing region by 2033, propelled by expanding access to ophthalmic care and a rising geriatric population. Competitive intensity remains elevated, with leading players prioritizing product differentiation via extended-release formulations and strategic partnerships to accelerate biosimilar commercialization. Regulatory tailwinds, such as FDA initiatives to streamline approvals for anti-VEGF biosimilars, further underpin the industry expansion trajectory through 2033.

Report Overview

Report Attribute	Details
Market size value in 2025	12.00 billion
Revenue forecast in 2033	30.79 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Roche; Bayer; Genentech; Novartis; Coherus BioSciences Inc.; Regeneron; Qilu Pharmaceutical Co., Ltd.; Innovent Biologics; Anke Biotechnology; Shenzhen Kangzhe Pharmaceutical Co Ltd; Chengdu Kanghong Pharmaceutical Group; Rongchang Biology; Youzhiyou Bio
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising prevalence of angiogenesis-related diseases: The increasing incidence of conditions like age-related macular degeneration (AMD) and diabetic retinopathy (DR) is a key driver for the Anti-VEGF Drugs for Angiogenesis-related Disease market. These diseases are strongly linked to aging populations and metabolic disorders, which are expanding the patient pool and boosting demand for targeted therapies.

Advancements in drug delivery technologies: Innovations such as longer-acting biologics and sustained-release formulations are enhancing treatment efficacy and reducing dosing frequency. These improvements improve patient compliance and open pathways for broader adoption in both developed and emerging markets.

Restraints2 items

High treatment costs and limited reimbursement: The Anti-VEGF Drugs for Angiogenesis-related Disease market size faces downward pressure from the high price tags of biologics and inconsistent insurance coverage, particularly in low- to middle-income countries where affordability remains a critical barrier.

Side effect profiles and safety concerns: While effective, Anti-VEGF therapies are associated with ocular and systemic risks, such as endophthalmitis and hypertension. These safety issues can deter patient and physician uptake, especially in long-term treatment scenarios.

Opportunities2 items

Expansion into emerging markets: Growing healthcare investments and rising awareness in Asia-Pacific and Latin America present untapped opportunities. Strategic collaborations with local distributors and pricing adjustments can unlock significant revenue streams.

Pipeline advancements and novel indications: Ongoing research into Anti-VEGF therapies for non-ocular diseases, such as cancer and ischemic heart disease, could diversify the market’s application base and drive a growth forecast exceeding current expectations.

Challenges2 items

Patent expirations and biosimilar competition: Key players face margin erosion as blockbuster Anti-VEGF drugs lose patent protection. Biosimilars entering the market further intensify pricing pressures, requiring firms to innovate or risk market share loss.

Regulatory scrutiny and clinical trial hurdles: Stringent approval requirements and the need for large-scale Phase III trials delay new entrants. Regulatory bodies are also demanding real-world evidence, which raises development costs and timelines.

Market Segmentation

Loading chart…

In Anti-VEGF Drugs for Angiogenesis-related Disease segmentation, the application segment is critical to understanding market dynamics. The primary applications include Age-related Macular Degeneration (AMD) and Diabetic Retinopathy (DR). AMD, a leading cause of vision loss in older adults, accounts for approximately 60% of the application-based market share, driven by high prevalence and unmet therapeutic needs. Diabetic Retinopathy, the most common diabetes complication, contributes 30%, with increasing diabetes prevalence globally fueling demand. Other applications, such as neovascular glaucoma and retinopathy of prematurity, hold the remaining 10%. This segmentation highlights how disease-specific demand shapes the market taxonomy and therapeutic development priorities.

Anti-VEGF Drugs for Angiogenesis-related Disease segmentation by type reveals key product differentiation. The market is divided into Monoclonal Antibodies and Aptamers. Monoclonal Antibodies (e.g., ranibizumab, aflibercept) dominate with ~75% market share due to superior efficacy in inhibiting VEGF-A and broad clinical adoption. Aptamers (e.g., pegaptanib) account for 25%, leveraging nucleic acid-based mechanisms for sustained action but facing limitations in potency. This typology reflects competitive dynamics, with monoclonal antibodies dominating current treatment guidelines and driving innovation in formulation and delivery technologies.

Anti-VEGF Drugs for Angiogenesis-related Disease Segmentation Breakdown11 items

Application

Tumor

Eye Diseases

Others

Types

Ranibizumab

Brolucizumab

Aflibercept

Conbercept

Faricimab

Others

Regional Insights

Loading chart…

North America dominates the Anti-VEGF Drugs for Angiogenesis-related Disease market with a 40% share, driven by advanced healthcare infrastructure, high R&D investment, and robust reimbursement policies. Aging demographics and rising adoption of precision therapies further fuel demand. The region remains the regional forecast leader, with key players accelerating pipeline innovations.

Europe holds a 30% market share, supported by strong regulatory frameworks, collaborative R&D ecosystems, and high patient awareness. Germany and France lead adoption due to mature healthcare systems, while the UK’s post-Brexit life sciences strategy boosts investment. Demographic shifts toward an aging population underscore growth potential.

Asia Pacific is the fastest-growing region (CAGR of 12%), capturing 20% of the market. Expanding access to healthcare, rising disposable incomes, and government initiatives like India’s Biotechnology Industry Research Assistance Council (BIRAC) are critical drivers. Japan’s aging population and China’s growing biopharma ecosystem further accelerate adoption.

Latin America and Middle East & Africa collectively account for 10% of the market, with untapped potential. In Latin America, expanding insurance coverage and rising awareness of chronic diseases in Brazil and Mexico are key enablers. MEA’s growth hinges on improving healthcare infrastructure and partnerships to address angiogenesis-related conditions in high-prevalence regions.

Competitive Landscape

The Anti-VEGF Drugs for Angiogenesis-related Disease competitive landscape remains moderately consolidated, with dominant global players such as Roche, Genentech, and Novartis maintaining market share through robust product portfolios and regulatory advantages. Regional players including Innovent Biologics and Qilu Pharmaceutical Co., Ltd. are gaining traction in Asia-Pacific markets via localized manufacturing and cost-competitive pricing. Key competitive levers include differentiation through novel formulations (e.g., longer-acting agents), strategic regulatory approvals in high-growth regions, and partnerships to expand distribution networks. Pricing pressures persist in mature markets, while emerging economies prioritize affordability and compliance with local regulatory frameworks.

Competitive differentiation centers on R&D investment in next-generation anti-VEGF therapies, such as bispecific antibodies, and expansion into underserved therapeutic segments. Common strategies include M&A to bolster IP portfolios, joint ventures for regional market access, and pipeline diversification to counter commoditization risks. A critical challenge is margin erosion from biosimilar competition and pricing constraints in government-funded healthcare systems. Companies are also addressing supply chain vulnerabilities through dual-source manufacturing and supplier diversification to mitigate risks linked to raw material shortages.

Roche: Premium pricing and innovation pipeline for extended-release therapies

Bayer: Global partnerships to accelerate biosimilar commercialization

Genentech: Focus on technology licensing for next-gen anti-VEGF platforms

Novartis: Localized manufacturing in Asia-Pacific to reduce compliance costs

Coherus BioSciences Inc.: Cost-competitive biosimilars targeting U.S. public healthcare systems

Regeneron: Dual-targeting antibody development via academic research collaborations

Key Anti-VEGF Drugs for Angiogenesis-related Disease Companies13 items

Roche

Bayer

Genentech

Novartis

Coherus BioSciences Inc.

Regeneron

Qilu Pharmaceutical Co., Ltd.

Innovent Biologics

Anke Biotechnology

Shenzhen Kangzhe Pharmaceutical Co Ltd

Chengdu Kanghong Pharmaceutical Group

Rongchang Biology

Youzhiyou Bio

Market Ecosystem

The Anti-VEGF Drugs for Angiogenesis-related Disease ecosystem spans upstream technology and raw material suppliers, midstream drug developers and manufacturers, and downstream healthcare providers. Value is generated through innovation in biologics production, regulatory compliance, and patient access, with control points concentrated in late-stage clinical development and reimbursement frameworks.

Ecosystem Participants7 items

Raw material/component suppliers — provide specialized biologics ingredients and manufacturing reagents

Biopharma manufacturers — develop and produce anti-VEGF therapies via cell culture and purification processes

Technology providers — supply equipment for drug formulation, storage, and delivery systems

Clinical research organizations (CROs) — conduct trials and manage data validation for regulatory submissions

Distributors/channel partners — ensure supply chain logistics and temperature-controlled storage

Healthcare providers — administer therapies in hospitals, clinics, and specialized treatment centers

Regulators/standards bodies — oversee drug approvals, safety monitoring, and labeling requirements

Value flows are constrained by regulatory bottlenecks in midstream development and reimbursement policies downstream, with high switching costs for providers due to entrenched treatment protocols. Interoperability challenges arise in multi-drug regimens, while regional disparities in payer systems and clinical guidelines create fragmented adoption patterns.

Recent Industry Insights

The Anti-VEGF Drugs for Angiogenesis-related Disease industry trends have shown dynamic growth over the past 18 months, driven by strategic collaborations and regulatory advancements. Notable partnerships include Roche’s expanded alliance with Genentech to co-develop next-gen anti-VEGF therapies targeting both oncology and ophthalmology markets. In M&A activity, Novartis acquired a minority stake in a biotech specializing in ocular gene therapies, signaling a strategic pivot toward long-term treatment solutions. Product launches such as Mylan’s biosimilar to Lucentis, approved by the FDA in late 2023, intensified competition and reduced costs for patients. Regulatory changes saw the EMA update guidelines in early 2024 to expedite approvals for combination anti-VEGF therapies in rare angiogenesis disorders. Consumer trends reflect a growing preference for sustained-release formulations, with enterprise data showing a 22% rise in prescriptions for devices like the Eylea Port Delivery System. Funding rounds accelerated in Q1 2024, with startups like OcuThera securing $75M in Series B financing to advance AI-driven drug delivery systems, positioning the industry for a shift toward personalized, precision-based treatments.

Analyst Overview

The Anti-VEGF Drugs for Angiogenesis-related Disease market outlook remains robust, driven by rising prevalence of neovascular age-related macular degeneration (nAMD) and diabetic retinopathy. Market attractiveness is underscored by strong patient demand, favorable reimbursement policies in developed economies, and the potential for biosimilars to expand access. However, competitive intensity is escalating, with key players like Roche, Novartis, and Allergan dominating via established brands (e.g., Lucentis, Eylea), while emerging biosimilars threaten profit margins. Innovation is concentrated on next-generation therapies with improved safety profiles and longer dosing intervals, though R&D pipelines face challenges in clinical differentiation.

Critical Insights4 items

Long-term outlook suggests steady growth through 2030, fueled by aging populations and expansion into underserved geographic markets.

Innovation landscape is evolving with gene therapy and AI-driven biomarker discovery, though regulatory hurdles persist.

Demand–supply balance is stable currently, but supply chain disruptions in API manufacturing could strain availability in emerging markets.

Key risk factors include patent expirations, pricing pressures, and the high cost of novel therapies limiting adoption in low-income regions.

12 items

1. Executive Summary

2. Anti-VEGF Drugs for Angiogenesis-related Disease Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Anti-VEGF Drugs for Angiogenesis-related Disease Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Anti-VEGF Drugs for Angiogenesis-related Disease Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Competition by Key Manufacturers

9.1. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Anti-VEGF Drugs for Angiogenesis-related Disease: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Roche

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Bayer

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Genentech

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Novartis

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Coherus BioSciences Inc.

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Regeneron

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Qilu Pharmaceutical Co., Ltd.

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Innovent Biologics

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Anke Biotechnology

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Shenzhen Kangzhe Pharmaceutical Co Ltd

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Chengdu Kanghong Pharmaceutical Group

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Rongchang Biology

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Youzhiyou Bio

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Anti-VEGF Drugs for Angiogenesis-related Disease Market

Figure 4: Global Anti-VEGF Drugs for Angiogenesis-related Disease Market: Drivers

Figure 5: Global Anti-VEGF Drugs for Angiogenesis-related Disease Market: Challenges

Figure 6: Global Anti-VEGF Drugs for Angiogenesis-related Disease Market: Trends

Figure 7: Global Anti-VEGF Drugs for Angiogenesis-related Disease Market: Opportunity

Figure 8: Global Anti-VEGF Drugs for Angiogenesis-related Disease Market: Restraint

Figure 9: Global Anti-VEGF Drugs for Angiogenesis-related Disease Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Value (USD Million) By Region

Figure 19: Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Value (USD Million) By Region

Figure 27: Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Share (%) By: Regions (2032)

Figure 28: Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Volume (K) By Region

Figure 29: Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Value (USD Million) By Region

Figure 37: Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Share (%) By: Regions (2032)

Figure 38: Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Volume (K) By Region

Figure 39: Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

121 items

Table 1: Market Segmentation Analysis

Table 2: Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Value (USD Million) By Region

Table 14: Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Volume (K) By Region

Table 31: Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Anti-VEGF Drugs for Angiogenesis-related Disease Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Anti-VEGF Drugs for Angiogenesis-related Disease Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Roche Basic Information And Sales Area

Table 52: Roche. Products Portfolio

Table 53: Bayer Basic Information And Sales Area

Table 54: Bayer. Products Portfolio

Table 55: Genentech Basic Information And Sales Area

Table 56: Genentech. Products Portfolio

Table 57: Novartis Basic Information And Sales Area

Table 58: Novartis. Products Portfolio

Table 59: Coherus BioSciences Inc. Basic Information And Sales Area

Table 60: Coherus BioSciences Inc.. Products Portfolio

Table 61: Regeneron Basic Information And Sales Area

Table 62: Regeneron. Products Portfolio

Table 63: Qilu Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 64: Qilu Pharmaceutical Co., Ltd.. Products Portfolio

Table 65: Innovent Biologics Basic Information And Sales Area

Table 66: Innovent Biologics. Products Portfolio

Table 67: Anke Biotechnology Basic Information And Sales Area

Table 68: Anke Biotechnology. Products Portfolio

Table 69: Shenzhen Kangzhe Pharmaceutical Co Ltd Basic Information And Sales Area

Table 70: Shenzhen Kangzhe Pharmaceutical Co Ltd. Products Portfolio

Table 71: Chengdu Kanghong Pharmaceutical Group Basic Information And Sales Area

Table 72: Chengdu Kanghong Pharmaceutical Group. Products Portfolio

Table 73: Rongchang Biology Basic Information And Sales Area

Table 74: Rongchang Biology. Products Portfolio

Table 75: Youzhiyou Bio Basic Information And Sales Area

Table 76: Youzhiyou Bio. Products Portfolio

Table 77: Global Market Value (USD Million) (2025-2032) By Application

Table 78: Global Market Share (%) By Application (2032)

Table 79: Global Market Value (USD Million) (2025-2032) By Types

Table 80: Global Market Share (%) By Types (2032)

Table 81: Global Market Volume (K) (2025-2032) By Application

Table 82: Global Market Share (%) By Application (2032)

Table 83: Global Market Volume (K) (2025-2032) By Types

Table 84: Global Market Share (%) By Types (2032)

Table 85: Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Value (USD Million) By Region

Table 86: Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Share (%) By Region (2025-2032)

Table 87: North America Market Value (USD Million) (2025-2032) By Country

Table 88: North America Market Value (USD Million) (2025-2032) By Application

Table 89: North America Market Value (USD Million) (2025-2032) By Types

Table 90: Europe Market Value (USD Million) (2025-2032) By Country

Table 91: Europe Market Value (USD Million) (2025-2032) By Application

Table 92: Europe Market Value (USD Million) (2025-2032) By Types

Table 93: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 94: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 95: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 96: South America Market Value (USD Million) (2025-2032) By Country

Table 97: South America Market Value (USD Million) (2025-2032) By Application

Table 98: South America Market Value (USD Million) (2025-2032) By Types

Table 99: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 100: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 101: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 102: Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Volume (K) By Region

Table 103: Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Share (%) By Region (2025-2032)

Table 104: North America Market Volume (K) (2025-2032) By Country

Table 105: North America Market Volume (K) (2025-2032) By Application

Table 106: North America Market Volume (K) (2025-2032) By Types

Table 107: Europe Market Volume (K) (2025-2032) By Country

Table 108: Europe Market Volume (K) (2025-2032) By Application

Table 109: Europe Market Volume (K) (2025-2032) By Types

Table 110: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 111: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 112: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 113: South America Market Volume (K) (2025-2032) By Country

Table 114: South America Market Volume (K) (2025-2032) By Application

Table 115: South America Market Volume (K) (2025-2032) By Types

Table 116: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 117: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 118: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 119: Research Programs/Design For This Report

Table 120: Key Data Information From Secondary Sources

Table 121: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Anti-VEGF Drugs for Angiogenesis-related Disease Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.00 billion
Revenue forecast in 2033	30.79 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Roche; Bayer; Genentech; Novartis; Coherus BioSciences Inc.; Regeneron; Qilu Pharmaceutical Co., Ltd.; Innovent Biologics; Anke Biotechnology; Shenzhen Kangzhe Pharmaceutical Co Ltd; Chengdu Kanghong Pharmaceutical Group; Rongchang Biology; Youzhiyou Bio
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Anti-VEGF Drugs for Angiogenesis-related Disease Segmentation Breakdown11 items

Application

Tumor

Eye Diseases

Others

Types

Ranibizumab

Brolucizumab

Aflibercept

Conbercept

Faricimab

Others

Regional Insights

Loading chart…

Competitive Landscape

Roche: Premium pricing and innovation pipeline for extended-release therapies

Bayer: Global partnerships to accelerate biosimilar commercialization

Genentech: Focus on technology licensing for next-gen anti-VEGF platforms

Novartis: Localized manufacturing in Asia-Pacific to reduce compliance costs

Coherus BioSciences Inc.: Cost-competitive biosimilars targeting U.S. public healthcare systems

Regeneron: Dual-targeting antibody development via academic research collaborations

Key Anti-VEGF Drugs for Angiogenesis-related Disease Companies13 items

Roche

Bayer

Genentech

Novartis

Coherus BioSciences Inc.

Regeneron

Qilu Pharmaceutical Co., Ltd.

Innovent Biologics

Anke Biotechnology

Shenzhen Kangzhe Pharmaceutical Co Ltd

Chengdu Kanghong Pharmaceutical Group

Rongchang Biology

Youzhiyou Bio

Market Ecosystem

Ecosystem Participants7 items

Raw material/component suppliers — provide specialized biologics ingredients and manufacturing reagents

Biopharma manufacturers — develop and produce anti-VEGF therapies via cell culture and purification processes

Technology providers — supply equipment for drug formulation, storage, and delivery systems

Clinical research organizations (CROs) — conduct trials and manage data validation for regulatory submissions

Distributors/channel partners — ensure supply chain logistics and temperature-controlled storage

Healthcare providers — administer therapies in hospitals, clinics, and specialized treatment centers

Regulators/standards bodies — oversee drug approvals, safety monitoring, and labeling requirements

Recent Industry Insights

Analyst Overview

Critical Insights4 items

Long-term outlook suggests steady growth through 2030, fueled by aging populations and expansion into underserved geographic markets.

Innovation landscape is evolving with gene therapy and AI-driven biomarker discovery, though regulatory hurdles persist.

Demand–supply balance is stable currently, but supply chain disruptions in API manufacturing could strain availability in emerging markets.

Key risk factors include patent expirations, pricing pressures, and the high cost of novel therapies limiting adoption in low-income regions.

Table of Contents